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Pharmacologic management of steroid-induced psychosis: a review of patient cases
Steroid-induced psychosis is an adverse effect of 
corticosteroids related to the following:
● Delusions
● Hallucinations 
● Significantly obstructs ability to function
● Doses greater than 40 mg/day of prednisone 
Pathophysiology
● Poorly understood. 
● Cognitive decline and depression may be 
associated with shrinkage of the hippocampus 
during corticosteroid therapy. 
● Psychosis may be related to increased dopamine. 
Management
● Taper and/or discontinue the steroid.
● Additional pharmacologic interventions may be 
required.
● There is limited information to support formal 
management of affected patients.  
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Discussion
To review the efficacy and safety of medications used 
in the management of steroid-induced psychosis.
Methods
Figure 2. Method of Literature Search
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Conclusion
There is evidence to support the effectiveness of 
antipsychotics in adult patients with steroid-induced psychosis. 
Clinicians must be judicious in prescribing corticosteroids to 
minimize the risk of this preventable adverse drug event. 
Results
● Steroid-induced psychosis has a quick onset and can 
present with other psychiatric manifestations.
● Antipsychotics such as haloperidol and risperidone were the 
most used and may be clinically favored.
● All of the patients that were reviewed either improved or had 
complete resolution.
● No adverse events were reported.
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Figure 1. Possible Pathophysiology of Steroid-induced Psychosis
Limitations
● The sample size from case reports and a single case series 
was small with variances in describing treatment methods.
● Steroid-induced psychosis may be underrepresented in the 
literature.
● Primary literature that would have been suited for inclusion 
may have been inadvertently missed.
Results from databases using search terms.
N=579
Results after screening for possibly relevant 
literature and applying ProQuest filters.
N=60
Results after removing duplicates and 
applying inclusion and exclusion criteria to 
full-text articles.
N=13
Figure 3. Corticosteroid Doses of Patients Included in 
the Review
Results
Table 2. Select Results of the Review




(prednisone equivalent in average mg/day)
Onset of Psychosis from 
Steroid Initiation
Pharmacotherapeutic Intervention
Ahmad & Rasul, 1999 1 (F/55) Prednisone (60) 10 days Haloperidol 5 mg IV followed by 2 mg PO BID
Fischer & Kim, 2019 1 (M/49) Dexamethasone (66.67) 3 days Lorazepam; quetiapine
Hong et al., 2006 1 (F/48) Prednisolone (15) < 24 hours Haloperidol 5 mg; lorazepam 4 mg
Jacob et al., 2002 1 (M/26) Hydrocortisone (100); prednisolone (30) 10 days Haloperidol 2.5 mg TID; lorazepam 2 mg PRN
Koh et al., 2002 1 (M/40) Methylprednisolone (625); prednisolone (40) 10 days Lorazepam, risperidone
López-Medrano et al., 2002 1 (F/20) Prednisone (60) 3 days Clonazepam 0.5 mg PO BID; risperidone 2 mg PO BID
Marian et al., 2010 1 (F/24) Prednisolone (60) A few days Risperidone 2 mg
Milanlioglu & Güleç, 2011 1 (M/46) Methylprednisolone (1250) 2 days Risperidone 2 mg
Mulky & Debbarma, 2018 1 (M/38) Dexamethasone (40) 6 months Diazepam 5 mg; olanzapine 10 mg DIV
Olson & Lewis, 2017 1 (F/46) Triamcinolone (100) After 5
th session Clonazepam; lithium
Sato et al., 1998 1 (M/54) Betamethasone (23.33) 2 years Flunitrazepam; haloperidol; levomepromazine maleate
Silva & Tolstunov, 1995 1 (M/45) Dexamethasone (100) 4 days Haloperidol 1 mg IM every hour of sleep and PRN confusion; 
perphenazine initially 4 mg PO every 2 hours PRN anxiety, then 
increased to 16 mg PO QID 
Ward & George, 2016 1 (M/62) Methylprednisolone (100)
 
Within 1 week of 
methylprednisolone injection 
for exacerbation
Valproic acid; zuclopenthixol depot injection
F=Female, M=Male, IV=Intravenously, PO=By Mouth, BID=Twice a Day, TID=Three Times a Day, PRN=As Needed, DIV=Divided Doses, QID=Four Times a Day
Medications
Available in the U.S.
Number of Patients 
Who Received Agent 
Haloperidol 5
Perphenazine 1
Risperidone 4
Olanzapine 1
Quetiapine 1
Lithium 1
Valproic acid 1
Lorazepam 4
Clonazepam 2
Diazepam 1
Contact Information
Grace Huynh: ghuynh@patriots.uttyler.edu
